H.C. Wainwright analyst Oren Livnat raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $217 from $200 and keeps a Buy rating on the shares. The firm updated the company’s estimates to reflect the Q4 report and 2025 guidance. It believes the acquisition of Chimerix brings a “rare” oncology asset and should be highly accretive.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- Jazz Pharmaceuticals assumed with an Overweight at Morgan Stanley
- Positive Outlook for Jazz Pharmaceuticals: Buy Rating Backed by Strong Growth Prospects and Strategic Focus
- Jazz Pharmaceuticals upgraded to Buy from Neutral at UBS
- Jazz Pharmaceuticals price target raised to $230 from $220 at Truist
- Strategic Acquisition of Chimerix Enhances Jazz Pharmaceuticals’ Oncology Portfolio and Supports Buy Rating
Questions or Comments about the article? Write to editor@tipranks.com